Source link : https://www.newshealth.biz/health-news/tirzepatide-shows-improvements-in-mash-resolution-fibrosis/
MILAN — Tirzepatide, a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) receptor agonist, was more effective than placebo was in the resolution of metabolic dysfunction–associated steatohepatitis (MASH) and in the improvement of fibrosis, according to the results of the phase 2 SYNERGY-NASH trial. Specifically, 44%-62% of participants with MASH and moderate or severe […]
Author : News Health
Publish date : 2024-06-10 22:09:59
Copyright for syndicated content belongs to the linked Source.
Categories